Loading...
Back to narrative

NNOX Will Benefit From Expanding AI Imaging Partnerships And Growing Global Deployments

Rising Regulatory Hurdles Will Test Digital Imaging But Allow Revival

NNOX logo
NNOX
AnalystLowTarget
Not Invested
Published 24 Aug 2025

Update shared on 12 Dec 2025

Fair value Increased 17%
n/a
n/a
AnalystLowTarget's Fair Value
n/a
Loading
1Y
-56.1%
7D
-10.3%

Analysts have raised their price target on Nano-X Imaging by approximately 17 percent to reflect stronger projected revenue growth and modestly improved long term profitability, which is partially offset by a slightly higher discount rate and a lower assumed future price to earnings multiple.

What's in the News

  • Nano-X Imaging completed a registered direct follow on equity offering of approximately $15 million, issuing 3,826,530 ordinary shares at $3.92 per share to support growth initiatives (company filing).
  • The company issued 2026 revenue guidance, targeting approximately $35 million in sales as commercialization ramps across imaging systems and AI solutions (company guidance).
  • Nano-X announced a strategic reseller partnership with 3DR Labs, enabling Nanox.AI software distribution to more than 1,800 hospitals and imaging centers across North America (company announcement).
  • Nanox expanded its European footprint with new collaborations in France and the Czech Republic to deploy the Nanox.ARC system and generate additional clinical evidence following CE Mark certification (company announcements).
  • The company plans to showcase the FDA cleared Nanox.ARC X system and unveil new AI solutions, including a pulmonary nodule tool and innovations for aortic valve calcification and body composition, at RSNA 2025 in Chicago (event announcement).

Valuation Changes

  • Fair Value Estimate has risen slightly to 7.0 from 6.0, reflecting stronger growth expectations and marginally better profitability.
  • Discount Rate has increased modestly to 8.52 percent from 8.34 percent, slightly reducing the present value of future cash flows.
  • Revenue Growth has risen significantly to approximately 80.3 percent from 61.1 percent, indicating more optimistic top line projections.
  • Net Profit Margin has improved slightly to about 5.45 percent from 5.39 percent, signaling only modest upgrades to long term profitability.
  • Future P/E Multiple has fallen meaningfully to about 159x from 222x, implying a more conservative valuation framework despite higher growth.

Have other thoughts on Nano-X Imaging?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

Disclaimer

AnalystLowTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystLowTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystLowTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.